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Abstract: The purpose of this work was to study the distribution of oleacein (OLEA) and its metabo-
lites in rat plasma and different tissues, namely brain, heart, kidney, liver, lung, small intestine, spleen,
stomach, skin, and thyroid, following the acute intake of a refined olive oil containing 0.3 mg/mL
of OLEA. For this purpose, a distribution kinetics study was carried out. The plasma and tissues
were collected at 1, 2, and 4.5 h after the intervention, and analyzed by LC-ESI-LTQ-Orbitrap-MS.
Unmetabolized OLEA was detected in the stomach, small intestine, liver, plasma and, most notably,
the heart. This finding may be useful for the development of new applications of OLEA for cardiovas-
cular disease prevention. Noteworthy are also the high levels of hydroxytyrosol (OH-TY) and OLEA
+ CH3 found in the small intestine, liver, and plasma, and the detection of nine OLEA metabolites,
five of them arising from conjugation reactions. Liver, heart, spleen, and lungs were the target tissues
where the metabolites were most distributed. However, it is important to note that OH-TY, in our
experimental conditions, was not detected in any target tissue (heart, spleen, thyroids, lungs, brain,
and skin). These results shed further light on the metabolism and tissue distribution of OLEA and
contribute to understanding the mechanisms underlying its effect in human health.
Keywords: biotransformation; extra virgin olive oil; hydroxytyrosol; phenolic compound; secoiridoid
1. Introduction
Oleacein (OLEA), also termed 3,4-DHPEA-EDA, plays a significant role in the organolep-
tic qualities of extra virgin olive oil (EVOO), and its antioxidant properties improve the
oil’s shelf life [1,2]. It is one of the most abundant compounds in EVOO and the concentra-
tions of this secoiridoid can reach up to 1834 ± 110 mg/kg [3,4]. OLEA is also reported
to have biological and pharmacological activities with wide-ranging health benefits. In
2012, an in vitro study showed that OLEA may offer far more protection against reactive
oxygen/nitrogen species-induced injury of human biomolecules than its parent compound
oleuropein [5]. It offers protection against cardiovascular diseases, decreasing the risk of
atherosclerosis [6–8], ischemic stroke [9], and hypertension [10]. Anti-cancer effects have
also been reported, including antiproliferative and apoptosis-inducing activity in leukemia
cells [11] and reduction of viability and migration of non-melanoma skin cancer cells [12].
An in vitro study found that OLEA has significant anti-tumor activity by promoting cell
cycle arrest and apoptosis [13]. Moreover, OLEA has been associated with healthy aging in
both in vitro and in vivo studies [14]. Anti-inflammatory properties provide OLEA with a
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protective effect against several metabolic abnormalities, including dyslipidemia, insulin
resistance, and glucose intolerance [15,16].
Despite numerous studies on the biological activity of OLEA, its tissue distribution is
not well documented. To date, only one study has focused on elucidating the absorption of
OLEA, through simultaneous sampling from the luminal perfusate and mesenteric blood,
and its metabolism during enterocytic transfer in the ileum [17]. In addition, the stability
of OLEA under low pH conditions and permeability in Caco-2 cells, and in isolated rat
intestine has been studied [18] as well as its fecal microbial metabolism in vivo [19]. The
distribution and accumulation of EVOO polyphenols [20] and oleocanthal [21] has also
been determined in rat tissues. The health-enhancing properties of OLEA cannot be fully
understood without further analysis of its absorption, tissue distribution, metabolism, and
excretion.
In this context, we carried out a qualitative and quantitative evaluation of OLEA and
its metabolites in a range of biological samples taken from rats at different times (0, 1, 2,
and 4.5 h) following the administration of refined olive oil (ROO) containing OLEA. For
the first time, OLEA and its metabolites were studied in organs of the digestive system
(stomach, small intestine, and liver), excretory tissue (kidney), and several target tissues
(heart, spleen, thyroids, lungs, brain, and skin).
2. Materials and Methods
2.1. Chemicals and Reagents
The reference standard OLEA (≥90%) was purchased from Toronto Research Chemi-
cals (North York, ON, Canada) and hydroxytyrosol (OH-TY) was obtained from Extrasyn-
these (Genay, France). The reagents methanol, acetonitrile (ACN), and formic acid were
acquired from AppliChem, Panreac Quimica SLU (Barcelona, Spain). Ultrapure water was
obtained using a Milli-Q purification system (Millipore, Bedford, MA, USA).
2.2. Animals
In this study, male Sprague–Dawley rats (body weight 227 ± 11 g) were obtained from
Envigo RMS Spain SL (Sant Feliu de Codines, Barcelona, Spain). The animals were accli-
mated for at least 1 week before the initiation of dosing with free access to food and water.
They were kept at 22 ± 2 ◦C in an air-conditioned room on a 12-h light–12-h dark cycle.
Before the experiments, the animals were fasted overnight with water available ad libitum.
The experiments were performed in compliance with the Animal Experimentation Ethics
Committee of the University of Barcelona, Spain and were approved by the Generalitat de
Catalunya (trial no. CEEA 124/16 and no. 6435, respectively).
2.3. Refined Olive Oil
Before the experiment, the ROO (used as a vehicle to dissolve OLEA for intragastric
administration) was analyzed by LC-ESI-LTQ-Orbitrap-MS to make sure it was free of
phenolic compounds. The liquid–liquid extraction of phenolic compounds in the ROO
was performed following previously described procedures [22]. The chromatographic and
mass spectrometer conditions were the same as used for the identification of metabolites
(Section 2.6). Once the absence of phenolic compounds was confirmed, the OLEA was
added to obtain a final concentration of 0.3 mg/mL. This concentration was chosen based
on its concentration in commercial EVOO (around 300 mg/kg), and the daily ingestion
recommended by the European Food Safety Authority of at least 5 mg of hydroxytyrosol
and its derivatives per 20 g of olive oil [23].
2.4. Dosage Information
The rats were divided into three different groups according to the time of euthanasia:
1 h (n = 4), 2 h (n = 5), and 4.5 h (n = 4). At 0 h, ROO loaded with OLEA standard was sup-
plied to the rats (2.5 mL/300 g body weight) by intragastric administration. Additionally,
a control group of rats was maintained under fasting conditions without olive oil ingestion
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and then similarly euthanized. The gavage volume was established following a good
practice guide for substance administration [24] and was lower than the maximum volume
of lipid vehicles per kg of rat body weight that prevents elevated plasma corticosterone
levels [25].
The rats were anesthetized with isoflurane (IsoFlo, veterinaria Esteve, Barcelona,
Spain) and euthanized by exsanguinations at the aforementioned time points after the
ROO ingestion. Blood samples were collected in EDTA tubes, centrifuged to obtain the
plasma (3000× g, 10 min at 4 ◦C), and stored at −80 ◦C until analysis. The gastrointestinal
tract (including stomach and small intestine), heart, spleen, thyroids, lungs, brain, kidney,
and skin were removed from rats at the designated time points. All tissues were washed
with saline solution (NaCl 0.9%) and dried with filter paper. In the case of the intestine, the
portion removed was 15 cm from 2 cm posterior to the pyloric sphincter, and the intestine
was also washed internally by perfusing the isotonic saline solution several times. Rat
tissues were accurately weighed and stored at −80 ◦C until analysis.
2.5. Sample Pre-Treatment for OLEA Metabolite Analysis
For extraction, all samples were slowly thawed in ice. To avoid compound oxidation,
the samples were handled in a room with filtered light and kept on ice throughout. The
clean-up of the biological matrix (protein precipitation) was performed using a previously
developed method [21].
2.5.1. Plasma
Plasma samples were centrifuged for 10 min (11,000× g, 4 ◦C). Briefly, 100 µL of each
sample was deproteinized with ice-cold ACN acidified with formic acid (2%) in a 1:5 (v/v)
ratio. The samples were then homogenized for 1 min and kept at −20 ◦C in a freezer for
20 min. After that, samples were centrifuged (11,000× g, 4 ◦C, 10 min) and finally, 100 µL
of each organic phase was transferred to vials for analysis.
2.5.2. Tissues
A small tissue disruptor (T 10 basic ULTRA-TURRAX®, IKA laboratory technology,
Staufen, Germany) was used to homogenize the thawed tissues in a 1:1 ratio (w/v) with
water:ACN (1:1 (v/v) with 0.1% ascorbic acid). The samples were then sonicated for 5 min
in an ice bath, shaken for 1 min (Vortex-Genie 2) and centrifuged for 10 min (11,000× g,
4 ◦C). To precipitate the proteins, a volume of 100 µL of the upper layer was blended with
cold ACN acidified with formic acid (2%) in a 1:3 (v/v) ratio. After that, the samples were
homogenized for 1 min and kept at −20 ◦C in a freezer for 20 min. Finally, the samples
were centrifuged for 10 min (11,000× g, 4 ◦C) and 100 µL of supernatant was transferred to
vials for analysis.
2.6. Instruments and Analytical Conditions
The metabolic profile was determined by analyzing the samples with LC-ESI-LTQ-
Orbitrap-MS. The equipment was an Accela chromatograph (Thermo Scientific, Hemel
Hempstead, UK) with a quaternary pump, a photodiode array detector (PDA) and a
thermostated autosampler coupled with a LTQ Orbitrap Velos mass spectrometer (Thermo
Scientific, Hemel Hempstead, UK) equipped with an ESI source in negative mode.
Chromatographic separation was performed using an AcquityTM UPLC® BEH C18
Pre-Column (2.1 × 5 mm, i.d., 1.7 µm particle size) and an AcquityTM UPLC® BEH
C18 Column (2.1 × 100 mm, i.d., 1.7 µm particle size) (Waters Corporation®, Ireland)
maintained at 50 ◦C. The mobile phases consisted of methanol (A) and H2O (B), both with
0.1% of formic acid. The elution was performed by means of a decreasing linear gradient
(v/v) of B (t (min), %B), as follows: (0, 100); (2, 100); (6, 46.4); (8, 0); (9, 0); (9.1, 100); (11,
100). The injection volume and the flow rate were set to 5 µL and 0.6 mL/min, respectively.
The instrumental conditions for the LTQ Orbitrap Velos mass spectrometer were the
same as reported in our previous study [17]. The identification of OLEA and OH-TY was
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achieved using their respective commercially available standards. The identification of the
other metabolites was based on chromatographic elution time, chemical composition, and
MS/MS fragmentation pattern, also as performed previously [17].
For quantification purposes, the calibration curves were prepared with OLEA in
plasma and each blank isolated tissue (brain, heart, kidney, liver, lung, small intestine,
spleen, stomach, skin, and thyroid) in concentrations of 0.1 to 3 µg/mL. All calibration
curves presented R2 > 0.97. The results of all OLEA metabolites were calculated using the
peak area of the parent molecule and were expressed as nmol OLEA equivalents/mL or
nmol OLEA equivalents/g tissue.
2.7. Data Analysis
All statistical analyses were performed with Statgraphics Centurion XVI software
(Statpoint Technologies Inc., Warrenton, VA, USA). Data are presented as mean and stan-
dard deviation (SD). The assumption of normalization was checked with standardized bias
and standardized kurtosis. Statistical differences in the concentration of metabolites and
OLEA at different post-administration times (1, 2, and 4.5 h) for each compound and tissue
were evaluated using a one-way ANOVA, followed by the LSD post-hoc test. Differences
were considered statistically significant at p < 0.05.
3. Results and Discussion
3.1. Pre-Systemic Metabolism
The concentrations of OLEA and its derivatives in the stomach, small intestine, and
liver expressed as nmol OLEA equivalents/g tissue are presented in Table 1. The highest
concentration (Cmax) of OLEA in the stomach (8.73 ± 0.29 OLEA equivalents/g tissue)
was found at 1 h after acute ingestion of ROO, and it had significantly decreased by
16% at 2 h and by 34% at 4.5 h (p < 0.05). One explanation for this reduction is gastric
emptying, as OLEA was observed in the small intestine at 1 h post-ingestion. Another
possible cause is the acidic environment of the stomach and/or the presence of nonlipolytic
carboxylester hydrolases, which can contribute to a hydrolysis of OLEA, resulting in OH-
TY and elenolic acid (EA) [26]. Contradictory results about the gastric stability of OLEA
have been reported. In a recent in vivo study with rats by Pinto et al. [18], OLEA was found
to undergo a complete degradation in the gastric region, and only a partial hydrolysis
after incubation at pH 2.0 (releasing OH-TY), with about 67% of OLEA remaining after 4 h.
A partial hydrolysis was also observed in our study, as the amount of OLEA reaching the
small intestine was lower than in the stomach at the same time point (Table 1). The Cmax of
OLEA in the small intestine was reached after 1 h of ROO intake, decreasing successively
thereafter (by 25% and 77% at 2 h and 4.5 h, respectively) (p < 0.05). This reduction is
mainly attributable to its good permeability through the intestinal epithelium, as reported
recently [17], and transport to the liver (where notably OLEA was detected only at 1 h
post-ingestion). The low concentration of OLEA in the liver vs. the small intestine is
explained by the partial intestinal metabolism of OLEA during the absorption [17].
The metabolites OH-TY and EA released in the stomach were transported to the
small intestine, where they were absorbed. As shown in Table 1, similar amounts of these
compounds were found in the liver. Both compounds are weak basic organic aromatic
molecules with very low molecular weights (<250 g/mol) and moderate lipophilicity
(logP ~ 0.9), which favors their absorption through passive mechanisms [26,27]; their
detection in plasma confirmed their absorption (Table 2). Current data suggest OH-TY is
the only biologically active derivative of OLEA [28,29], so the detection of free OH-TY in
the liver is noteworthy, pointing to its potential application in the prevention of certain
hepatic diseases. Our results are in line with other studies that demonstrate that OH-TY
can reach the liver [30]. Our results, with regard to the OH-TY concentration in stomach
at 1 h, were similar to those reported in another study (8.75 ± 1.95 nmols/g digesta) [19],
demonstrating the degradation of OLEA at the stomach level.
Antioxidants 2021, 10, 1083 5 of 12
Table 1. Concentration of OLEA and phase I and phase II metabolites in the stomach, small intestine,
and liver, expressed as nmol OLEA equivalents/g tissue. Results are shown as the mean ± standard
deviation.
Metabolite (nmol OLEA
Equivalents/g Tissue) Time (h) Stomach Small Intestine Liver
OLEA
1 8.73 ± 0.29 a 2.24 ± 0.14 a 0.28 ± 0.02
2 7.39 ± 0.25 b 1.69 ± 0.25 b n.d.
4.5 5.77 ± 0.54 c 0.51 ± 0.10 c n.d.
OH-TY
1 13.37 ± 1.27 a 4.71 ± 0.32 a 3.34 ± 0.08 b
2 7.81 ± 0.69 b 3.79 ± 0.29 b 3.83 ± 0.21 a
4.5 5.23 ± 0.37 c 2.70 ± 0.21 c 2.51 ± 0.07 c
EA
1 7.53 ± 0.56 a 1.81 ± 0.05 a 1.07 ± 0.06 b
2 4.07 ± 0.36 b 0.67 ± 0.08 b 1.34 ± 0.08 a
4.5 1.81 ± 0.13 c 0.16 ± 0.02 c 0.76 ± 0.02 c
OLEA + H2
1 1.34 ± 0.01 a 5.31 ± 0.48 a n.d.
2 0.82 ± 0.01 b 3.01 ± 0.35 b n.d.
4.5 0.81 ± 0.01 b 2.16 ± 0.10 c n.d.
OLEA + H2O
1 1.90 ± 0.18 a 1.29 ± 0.14 a 0.33 ± 0.02 b
2 1.66 ± 0.12 a 0.96 ± 0.06 b 0.77 ± 0.01 a
4.5 0.80 ± 0.03 b 0.53 ± 0.01 c 0.26 ± 0.04 c
OLEA + CH3
1 0.46 ± 0.05 a 3.69 ± 0.19 a 3.88 ± 0.45 b
2 0.41 ± 0.01 a 2.99 ± 0.46 b 5.79 ± 0.36 a
4.5 0.26 ± 0.00 b 2.26 ± 0.22 c 1.90 ± 0.24 c
OLEA + H2O + CH3
1 n.d. n.d. 1.37 ± 0.12 b
2 n.d. n.d. 1.78 ± 0.07 a
4.5 n.d. n.d. 1.10 ± 0.07 c
OLEA + H2 + glucu
1 n.d. n.d. 0.77 ± 0.05 b
2 n.d. n.d. 1.18 ± 0.06 a
4.5 n.d. n.d. 0.46 ± 0.05 c
OLEA+ H2O + CH3 + glucu
1 n.d. n.d. 0.38 ± 0.03 b
2 n.d. n.d. 0.69 ± 0.04 a
4.5 n.d. n.d. 0.26 ± 0.01 c
Different letters in each metabolite and tissue indicate significant differences in concentration between 1, 2, and
4.5 h (p < 0.05). n.d. not detected.
Table 2. Mean concentration of OLEA and its phase I and phase II metabolites ± standard deviation





OLEA 1.37 ± 0.20 a 0.65 ± 0.07 b 0.67 ± 0.10 b
OH-TY 2.11 ± 0.10 b 3.02 ± 0.16 a 1.62 ± 0.14 c
EA 0.43 ± 0.03 b 0.76 ± 0.04 a 0.16 ± 0.02 c
OLEA + H2 0.87 ± 0.02 b 1.08 ± 0.02 a 0.87 ± 0.02 b
OLEA + H2O 0.91 ± 0.03 b 1.14 ± 0.02 a 0.84 ± 0.02 c
OLEA + CH3 2.52 ± 0.24 b 3.50 ± 0.18 a 2.80 ± 0.22 b
OLEA + H2O + CH3 1.04 ± 0.01b 1.35 ± 0.05 a 0.91 ± 0.02 c
OLEA + H2 + glucu 0.88 ± 0.04 b 1.10 ± 0.04 a 0.71 ± 0.02 c
OLEA + H2O + glucu 1.26 ± 0.03 b 1.44 ± 0.04 a 1.03 ± 0.03 c
OLEA + H2O + CH3 + glucu 0.57 ± 0.01 b 0.65 ± 0.01 a 0.50 ± 0.01 b
Different letters in each metabolite and tissue indicate significant differences in concentration between 1, 2 and
4.5 h (p < 0.05).
As shown in Table 1, the metabolite arising from the hydrogenation of OLEA (OLEA
+ H2) was detected in the stomach and small intestine, with the Cmax in both tissues at
2 h (p < 0.05). In previous studies, this metabolite was not identified in the stomach,
small intestine or liver [19,20], although it has been detected in human urine [31] and rat
plasma [17]. The hydrogenation of an aldehyde could be attributed to aldo–keto reductases
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(AKRs) that primarily reduce aldehydes and ketones to primary and secondary alcohols,
respectively [32]. In our study, the absence of the hydrogenated metabolite in the liver could
be attributed to other biotransformations once it reaches this tissue, such as glucuronidation.
It is well known that conjugation reactions lead to the formation of a covalent bond joining
a functional group in the parent compound or phase I metabolite [33].
The metabolite OLEA + H2O was detected in the stomach, small intestine, and liver
samples. The Cmax in the two first tissues was reached at 1 h, and in the liver at 2 h
(p < 0.05), reflecting the time required for absorption and transport. These results support
those described by García-Villalba et al. [31] and López-Yerena et al. [17], who identified
this metabolite in human urine and rat plasma, respectively. However, in other studies of
secoiridoid metabolism, this metabolite has not been quantified [18–20,34].
Regarding OLEA derivatives arising from conjugation reactions, a methylated metabo-
lite (OLEA + CH3) was detected in the stomach, small intestine, and the liver, with higher
concentrations in the latter two organs. In the liver, it was the metabolite with the highest
concentration. The catechol-O-methyltransferase (COMT) enzymes, most active in the liver
and kidneys, but also in the pylorus of the stomach and in the small intestine [35], are
responsible for the methylation of available OLEA. Glycoconjugated metabolites, on the
other hand, require the activity of uridine-disphosphate glucuronosyl transferase (UGT).
Although these enzymes are present in the stomach [36], and UGT1A8 and UGT1A10 are
exclusively expressed in the small intestine [37], the liver is the main site of glucuronida-
tion [36], which could explain why we found metabolites with a glucuronide acid only in
the liver and not in the stomach and small intestine. Regarding metabolites not derived
from hydrolysis reactions, their concentrations were very low (or even absent) in the stom-
ach and increased in the intestine and liver, in accordance with the higher qualitative and
quantitative enzyme endowment of these organs. These metabolites were also detected in
the intestinal lumen and ileal tissue by López-Yerena [17]. The fact that we did not find the
metabolites OLEA+ H2O + CH3, OLEA + H2 + glucu and OLEA + H2O + CH3 + glucu in
the small intestine (Table 1), yet they were detected in the aforementioned study (at very
low concentrations), can be mainly attributed to methodological differences (in situ vs. oral
administration).
3.2. Plasma
Table 2 shows the concentration of OLEA and its phase I and II metabolites detected
in rat plasma after the intragastric administration of OLEA in ROO. As can be observed,
OLEA reached the systemic circulation unchanged, being found in the plasma at all three
sampling times. The highest concentration was at 1 h post-ROO intake (1.37 ± 0.20 nmol
OLEA equivalents/mL), and some remained at 4.5 h (0.67 ± 0.10 nmol OLEA equiva-
lents/mL). Our results are in accordance with those of Silva et al. [34] who identified
unmetabolized OLEA in human plasma after EVOO intake. Recently, OLEA was also
detected in mesenteric rat plasma after in situ perfusion of the small intestine [17]; this
method avoided the pass through the stomach where hydrolysis can potentially take place,
but the OLEA would still have to pass through the liver to reach the systemic circulation.
In contrast with the present results, OLEA was not identified in rat plasma after the admin-
istration of a phenolic extract from olive cake [20] or a diet supplemented with OLEA [19].
The presence of OLEA in plasma at all sample times, unlike in the liver, where it was only
detected at 1 h, could be due to an in situ deconjugation in red blood cells, as suggested for
sulphates and glucuronidates of OH-TY [38].
The metabolites circulating in plasma at the highest concentrations were methylated
OLEA (OLEA+ CH3) and OH-TY. The Cmax of methylated OLEA was highest at 2 h post-
ingestion of ROO (3.50 ± 0.18 nmol OLEA equivalents/mL), representing 25% of the total
metabolites identified at this time point (p < 0.05). The second most abundant, OH-TY,
represented 20, 22% and 17% of the total metabolites at 1, 2, and 4.5 h, respectively. Our
results are similar to those of Serra et al. [20], who linked the high percentage of total phenyl
alcohol metabolites (e.g., OH-TY and tyrosol) in plasma with the high content of OLEA in
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the administered olive cake extract, which acted as a source of OH-TY. Contrary results
were observed by López de las Hazas et al. [39], who did not detect free OH-TY in human
plasma after the acute intake of an olive oil phenolic extract. Differences in metabolism
between rodents and humans may be the reason for these differences in results [40]. Other
reasons may include: (i) the vehicle, (ii) individual genomic profile (affecting enzymatic
activity involved in the digestion and metabolism processes), and (iv) polymorphism of
conjugation enzymes or individual variations in digestive enzymes or bile salts [34,40,41].
The detection of free OH-TY in plasma may shed light on the health benefits of the
phenolic content of EVOO. Interest in OH-TY has grown since 2012, when the European
Food Safety Agency (EFSA) Panel on Dietetic Products, Nutrition, and Allergies (NDA)
established a cause-and-effect relationship between the consumption of olive oil polyphe-
nols and protection of LDL particles from oxidative damage [28]. Based on this scientific
opinion, “Olive oil polyphenols contribute to the protection of blood lipids from oxidative
stress” was included in the list of authorized health claims in the European Union [29],
being the only relating polyphenols with health.
Other metabolites arising from phase I (EA, OLEA + H2 and OLEA + H2O) and phase
II reactions (OLEA + H2O + CH3, OLEA + H2 + glucu, OLEA + H2O + glucu, OLEA + H2O
+ CH3 + glucu) were also detected in plasma samples. For all metabolites, the Cmax was
reached at 2 h after ROO consumption. In another study, OLEA + H2O + CH3 + glucu was
also identified in human plasma [34].
3.3. Accumulation and Distribution of OLEA Derivatives in Rat Tissues
To date, only two studies have focused on the metabolism and distribution of sec-
oiridoids, including OLEA, in target tissues of rats [19,20]. The vehicles they used to
administer the phenolic compounds (pellets containing a secoiridoid extract and a phenolic
extract from olive cake dispersed in water, respectively) could be seen as a drawback when
attempting to elucidate the health effects of EVOO. In our study, ROO was chosen as the
vehicle to better simulate the conditions of EVOO consumption. In addition, the metabolite
profile was determined by UPLC coupled with high-resolution mass spectrometry (HRMS),
using Orbitrap technology to overcome the limitations of the low-resolution MS techniques
(triple quadrupole) of the two previous studies [19,20,42]. The main results are shown in
Table 3. It is important to note that both OH-TY and EA as well as their metabolites were
not detected in heart, spleen, thyroids, lungs, brain, kidney, and skin.
Table 3. Mean ± standard deviation of tissue concentration of metabolites, expressed as nmol OLEA equivalents/g tissue,




Time (h) Heart Spleen Thyroids Lungs Brain Kidney
OLEA
1 0.44 ± 0.07 a n.d. n.d. n.d. n.d. n.d.
2 0.45 ± 0.04 a n.d. n.d. n.d. n.d. n.d.
4.5 0.44 ± 0.06 a n.d. n.d. n.d. n.d. n.d.
OLEA + H2
1 0.17 ± 0.02 b 0.30 ± 0.05 c 0.10 ± 0.01 c 0.49 ± 0.04 c n.d. n.d.
2 0.30 ± 0.04 a 0.54 ± 0.03 a 0.24 ± 0.01 a 0.70 ± 0.05 a n.d. n.d.
4.5 0.18 ± 0.01 b 0.34 ± 0.02 b 0.12 ± 0.01 b 0.52 ± 0.01 b n.d. n.d.
OLEA + H2O
1 0.07 ± 0.01 b 0.42 ± 0.03 b 0.12 ± 0.02 b 0.49 ± 0.02 b 0.13 ± 0.03 b n.d.
2 0.17 ± 0.02 a 0.61 ± 0.07 a 0.24 ± 0.02 a 1.02 ± 0.12 a 0.22 ± 0.02 a n.d.
4.5 0.07 ± 0.01 b 0.42 ± 0.02 b 0.13 ± 0.03 b 0.42 ± 0.05 b 0.10 ± 0.01 b n.d.
OLEA + CH3
1 0.20 ± 0.02 b 0.31 ± 0.03 b 0.21 ± 0.02 b 0.35 ± 0.03 b 0.32 ± 0.03 b 0.17 ± 0.01 b
2 0.36 ± 0.03 a 0.39 ± 0.04 a 0.31 ± 0.02 a 0.45 ± 0.04 a 0.52 ± 0.04 a 0.20 ± 0.02 b
4.5 0.25 ± 0.03 b 0.27 ± 0.03 b 0.24 ± 0.01 b 0.31 ± 0.02 b 0.30 ± 0.03 b 0.34 ± 0.04 a





Time (h) Heart Spleen Thyroids Lungs Brain Kidney
OLEA + H2O + CH3
1 0.11 ± 0.01 b 0.18 ± 0.03 c 0.14 ± 0.01 b 0.62 ± 0.06 b 0.17 ± 0.02 b 0.13 ± 0.02 c
2 0.18 ± 0.03 a 0.68 ± 0.03 a 0.22 ± 0.03 a 0.84 ± 0.04 a 0.35 ± 0.02 a 0.23 ± 0.03 b
4.5 0.08 ± 0.01 c 0.44 ± 0.04 b 0.09 ± 0.09 c 0.48 ± 0.04 c 0.15 ± 0.02 b 0.43 ± 0.06 a
OLEA + H2 + glucu
1 0.13 ± 0.02 b 0.08 ± 0.01 b 0.17 ± 0.02 b 0.24 ± 0.01 b 0.28 ± 0.03 b 0.10 ± 0.02 c
2 0.20 ± 0.01 a 0.18 ± 0.01 a 0.28 ± 0.01 a 0.37 ± 0.01 a 0.40 ± 0.03 a 0.35 ± 0.13 b
4.5 0.11 ± 0.01 b 0.08 ± 0.01 b 0.07 ± 0.01 c 0.11 ± 0.02 c 0.09 ± 0.02 c 0.64 ± 0.03 a
OLEA + H2O + glucu
1 0.42 ± 0.07 a 0.30 ± 0.03 b 0.21 ± 0.02 b 0.32 ± 0.02 b 0.28 ± 0.03 b 0.20 ± 0.03 b
2 0.43 ± 0.06 a 0.43 ± 0.03 a 0.35 ± 0.05 a 0.45 ± 0.03 a 0.41 ± 0.03 a 0.25 ± 0.04 b
4.5 0.17 ± 0.02 b 0.13 ± 0.02 c 0.01 ± 0.02 c 0.15 ± 0.02 c 0.10 ± 0.02 c 0.91 ± 0.05 a
OLEA + H2O
+ CH3 + glucu
1 0.05 ± 0.00 c 0.11 ± 0.02 b n.d. 0.06 ± 0.01 b 0.04 ± 0.00 b 0.05 ± 0.00 c
2 0.20 ± 0.01 a 0.42 ± 0.04 a n.d. 0.10 ± 0.02 a 0.08 ± 0.01 a 0.14 ± 0.02 b
4.5 0.13 ± 0.01 b 0.05 ± 0.00 c n.d. 0.04 ± 0.01 b 0.05 ± 0.01 b 0.40 ± 0.02 a
Different letters in each metabolite and tissue indicate significant differences in concentration between 1, 2, and 4.5 h (p < 0.05). n.d. not
detected.
3.3.1. Heart
The heart was the only organ where unmetabolized OLEA was detected without
significant differences in concentration between the time points (p > 0.05) (0.44 ± 0.07,
0.45 ± 0.04 and 0.44 ± 0.06 nmol OLEA equivalents/g tissue, at 1, 2, and 4.5 h, respectively).
The effect of OLEA on the progression of different types of cardiovascular diseases has been
studied in vitro. These include biological effects, such as the ability to regulate low-density
lipoprotein (LDL) oxidation and myeloperoxidase (MPO) activity, to reduce the expression
of adhesion molecules through angiotensin II production, and to confer protection to
erythrocytes from oxidative hemolysis [5–9]. Although the concentrations detected in the
heart (≤0.5 nmol OLEA equivalents/g tissue) were very low compared with the results
of in vitro studies (50 and 100 mM [6] and 10–20 mM [7]), this is the first demonstration
that OLEA is able to reach the heart, where it may exert a beneficial effect. However, more
studies are necessary to determine if the concentration detected in our study would be
sufficient for OLEA to play a preventive and curative role against cardiovascular injury. In
addition to OLEA, seven metabolites were also detected (Table 3).
3.3.2. Spleen, Lungs and Thyroids
Seven metabolites in the spleen and lungs and six in thyroids were detected (Table 3),
all with a Cmax at 2 h after ROO ingestion. The activity of metabolizing enzymes in the
endothelial cells of lungs [43,44] and their expression in macrophages and lymphocytes in
the white pulp region of the spleen [20] could explain the presence of these metabolites in
these tissues.
3.3.3. Brain
The main metabolites found in the brain were from phase II reactions. The only phase
I metabolite quantified was the hydrated form of OLEA vs. five conjugated metabolites
detected in greater number and concentration. After 1 h of ROO ingestion, the main
metabolites identified were OLEA + CH3, OLEA + H2 + glucu, and OLEA + H2O +
glucu. Neurodegenerative diseases normally begin in the elderly, caused by a significant
accumulation of reactive oxygen species in the brain due to unknown causes. In neu-
rodegeneration, mitochondrial dysfunction, neuroinflammation, and in some pathologies,
protein aggregation and neuronal death culminate in brain dysfunction [45]. Recently,
Gutiérrez-Miranda et al. [46] suggested that OLEA may provide protective effects against
autoimmune encephalomyelitis by reducing leukocyte infiltration into the central nervous
system, preventing the formation of inflammatory mediators, and inhibiting the elevation
of the oxidative stress status. According to the results of our study, in which free OLEA
was not detected in the brain, more research is needed to determine the bioactivity of the
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main metabolites at the physiological concentrations achieved after regular consumption
of EVOO, or the potential intracellular deconjugation of the metabolites in the target tissue.
Additionally, it is important to note that although OH-TY has been shown to be capable
of reaching the brain [45], it was not detected in our study. Differences in administered
doses may explain these differences (5 mg/kg/day during 21 days vs. 0.3 mg/mL in an
acute study).
3.3.4. Kidneys
As shown in Table 3, only conjugated metabolites were detected in the kidneys, which
is the only organ where the highest concentration of metabolites was found at 4.5 h post-
ROO consumption (p < 0.05). As kidneys are an elimination organ, hydrophilic metabolites
are likely to accumulate there for excretion. At 4.5 h, the main metabolite identified was
OLEA + H2O + glucu, with a Cmax of 0.91 ± 0.05 nmol OLEA equivalents/g tissue. The
wide range of metabolites detected indicates that renal excretion is a major pathway of
OLEA metabolite elimination in rats. The presence of metabolites in the kidneys could
also be attributed to the activity of metabolic enzymes (CYP and UGT). By regulating renal
drug and chemical metabolic clearance, they modulate intra-renal exposure to compounds
as well as the activity of physiological mediators [47]. In 2010, Garcia Villalba et al. [31]
identified the same metabolites in human urine 2 h after the intake of olive oil.
3.3.5. Skin
The skin is the least studied tissue in distribution studies after a phenolic compound
ingestion. In a recent study of oleocanthal distribution, four metabolites were detected in
the skin [21], whereas we identified only OLEA + CH3. The concentration of this metabolite
increased over time: 0.09 ± 0.01, 0.15 ± 0.02 and 0.25 ± 0.02 nmol OLEA equivalents/g
tissue at 1, 2, and 4.5 h, respectively, achieving a Cmax at 4.5 h post-ingestion (results
not included in the Table 3). The skin is a relatively poorly perfused tissue compared to
well-perfused tissues like the lungs, heart, and thyroid gland, and therefore the compounds
reach it more slowly through the blood circulation [48]. Despite the detection of only
one metabolite in the skin, this finding may help to shed new light on the mechanisms
underlying EVOO phenolic compound activity in the body, specifically in the area of skin
disorder prevention.
4. Conclusions
In this work, the distribution of OLEA and derived metabolites in rat plasma and ten
organs/tissues was investigated using an LC-ESI-LTQ-Orbitrap-MS system. In our study,
a comprehensive study of plasma, stomach, small intestine, liver, heart, spleen, thyroids,
lungs, brain, kidney, and skin was performed after a single oral administration of OLEA in
ROO (by gastric gavage).
OLEA was detected in its free form in the stomach, and was also found to be hy-
drolyzed resulting in OH-TY and EA. Unmetabolized OLEA was also detected in the small
intestine, liver, plasma, and most interestingly, the heart. This finding may be useful for
the development of new applications of OLEA to prevent cardiovascular diseases. The
results may also shed light on why OLEA is active in vivo, even if its blood concentration is
low. Furthermore, the high levels of OH-TY and OLEA + CH3 found in the small intestine,
liver, and plasma are noteworthy. Regarding the metabolite profiles in tissues, up to seven
metabolites were identified. The liver, heart, spleen, and lungs were the target tissues
where the metabolites were detected to be greater. It is important to note that OH-TY
did not reach any of these tissues. The presence of parent and/or OLEA metabolites in
rat tissues could explain the myriad of health benefits attributed to EVOO consumption.
In summary, after the oral administration of OLEA, its metabolites were more widely
distributed in tissues and plasma than the parent compound.
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